How to build a biotech uni­corn: Get the star team in place, at­tract deep-pock­et VCs, paint a big pic­ture and raise up to $1B

When Steve Harr sketched out the bare­bones es­sen­tials of his strate­gic plan for the new cell ther­a­py com­pa­ny Sana Biotech­nol­o­gy a few days ago, he was care­ful to steer clear of de­tail­ing his ex­act plans for his first big raise for the biotech. But some num­bers have been start­ing to ap­pear — and not sur­pris­ing­ly they paint a pic­ture of a young uni­corn still at foal stage.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER